- Home
- XLO vs INMB Comparison
XLO vs INMB Comparison
Compare XLO & INMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XLO | INMB |
|---|---|---|
| Founded | 2016 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.8M | 40.1M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | XLO | INMB |
|---|---|---|
| Price | $0.57 | $1.44 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 1 | 3 |
| Target Price | $2.00 | ★ $4.30 |
| AVG Volume (30 Days) | ★ 572.5K | 332.6K |
| Earning Date | 03-10-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $31,804,000.00 | $50,000.00 |
| Revenue This Year | $626.78 | $264.29 |
| Revenue Next Year | $79.08 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 588.40 | 19.05 |
| 52 Week Low | $0.50 | $1.38 |
| 52 Week High | $1.70 | $11.64 |
Technical Indicators
Market Signals| Indicator | XLO | INMB |
|---|---|---|
| Relative Strength Index (RSI) | 45.49 | 41.81 |
| Support Level | $0.50 | $1.44 |
| Resistance Level | $0.61 | $1.67 |
| Average True Range (ATR) | 0.04 | 0.12 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 55.80 | 12.82 |
Price Performance
Historical ComparisonAbout XLO Xilio Therapeutics Inc.
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies and immune cell engagers.
About INMB INmune Bio Inc.
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.